Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United ...

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United ...

EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds through analysis of U.S. longitudinal ...

India-based Zydus Lifesciences’ US subsidiary Zydus Therapeutic has announced positive top-line results from the pivotal EPICS-III Phase IIb/III clinical trial. In this trial, the safety and efficacy ...

Higher activity of PGC-1α enables brown fat cells in females to achieve thermogenic activity and energy expenditure compared ...

T3D-959, an oral dual delta/gamma peroxisome proliferator-activated nuclear receptor (PPAR) agonist, has shown promise in a phase 2 randomized, placebo-controlled study of adults with mild-to-moderate ...

Scientists at Harvard Medical School have shown that in mice lacking amyloid beta (Aβ), the fundamental hallmark of Alzheimer's disease (AD), neurons died from ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting I. This abstract does not include a full text component.

The obesity rate has more than doubled in the last 30 years, affecting more than one billion people worldwide. This prevalent condition is also linked to other metabolic disorders, including type 2 ...

The European Medicines Agency (EMA) has swatted away Minoryx Therapeutics’ attempt to bring a rare disease drug candidate to market on the strength of a clinical trial that missed its primary endpoint ...